FOUSE JACQUALYN A 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Apr 10, 2025
Insider Transaction Report
Form 4
FOUSE JACQUALYN A
Director
Transactions
- Exercise/Conversion
Restricted stock units
2025-04-08−15,933→ 0 total→ Common stock (15,933 underlying) - Exercise/Conversion
Common stock
2025-04-08+15,933→ 156,717 total - Sale
Common stock
2025-04-10$25.90/sh−7,497$194,172→ 149,220 total
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated April 8, 2022.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.